Showing results (241-250 of 446) with videos related to
Sort By:
Pageof 45
Current Oncology Reports|September 24, 2024
Risk Stratification, Screening and Treatment of BRAF/MEK Inhibitors-Associated CardiotoxicityIsabelle Senechal, Maria Sol Andres, Jieli Tong, et al.Nature Communications|May 21, 2026
Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trialRebecca J Lee, Dominic G Rothwell, Nigel Smith, et al.Cancer Discovery|March 28, 2023
Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary PathwaysLavinia Spain, Alexander Coulton, Irene Lobon, et al.Cell|April 17, 2018
Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx RenalSamra Turajlic, Hang Xu, Kevin Litchfield, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 20, 2025
PSMA-Guided Metastasis-Directed Therapy for Oligometastatic Renal Cell Carcinoma: The Proof-of-Concept PEDESTAL StudyCristian Udovicich, Mathias Bressel, Jamil Manji, et al.The Journal of Pathology|May 30, 2013
Parallel evolution of tumour subclones mimics diversity between tumoursPierre Martinez, Nicolai Juul Birkbak, Marco Gerlinger, et al.European Journal of Cancer (Oxford, England : 1990)|December 28, 2014
PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxelNicholas Coupe, Pippa Corrie, Mirela Hategan, et al.Expert Review of Pharmacoeconomics & Outcomes Research|December 21, 2022
Real-world clinical outcomes and cost estimates of metastatic castration-resistant prostate cancer treatment: does sequencing of taxanes and androgen receptor-targeted agents matter?Amanda Pereira-Salgado, Angelyn Anton, Fanny Franchini, et al.European Journal of Cancer (Oxford, England : 1990)|June 8, 2019
Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinibKarl Lewis, Axel Hauschild, James Larkin, et al.BMC Health Services Research|July 4, 2026
Healthcare waste: from incineration to pyrolysis: a comparative life cycle assessment of two different healthcare plastic waste management processesBrett Duane, James Larkin, Marta Arias, et al.Pageof 45